50% Hemolysis Rate Test: Principles, Standards, Methods, and Applications

The 50% hemolysis rate test is a laboratory assay that quantifies the degree of red blood cell lysis caused by a material, extract, or biological sample, using the 50% hemolysis endpoint as the most sensitive and reproducible point of the lysis curve. It is a core component of blood biocompatibility evaluation for medical devices under ISO 10993-4, GB/T 16886.4, and ASTM F756, and it also underpins the classical CH50 assay for total complement activity in clinical immunology. This article explains the test principle, sample types, methods, calculation, acceptance criteria, and typical applications.

Technical Overview

The 50% hemolysis rate test measures the extent to which a test article disrupts the membrane of erythrocytes (red blood cells), causing the release of intracellular hemoglobin into the surrounding plasma or buffer. Because free hemoglobin absorbs strongly at approximately 540 nm to 545 nm, the extent of lysis can be quantified spectrophotometrically and expressed as a hemolysis rate (percentage) relative to fully lysed positive controls and non-lysed negative controls.

The "50%" designation refers to the midpoint of the hemolysis dose–response curve. At 50% lysis, the response curve is at its steepest, which means small changes in lytic activity produce the largest measurable change in absorbance. For this reason, the 50% hemolysis endpoint is regarded as the most sensitive, precise, and statistically reproducible point for quantifying lytic agents, whether the lytic factor is a device material, a chemical extract, or a complement protein cascade in serum.

Two major families of testing rely on this principle:

• Medical device hemolysis testing under ISO 10993-4 (Biological evaluation of medical devices – Part 4: Selection of tests for interactions with blood), GB/T 16886.4, and ASTM F756 (Standard Practice for Analysis of Hemolytic Properties of Materials), which evaluates whether blood-contacting devices damage erythrocytes.
• Clinical CH50 testing (50% hemolytic complement assay), which uses antibody-sensitized sheep erythrocytes and the 50% lysis endpoint, usually resolved with the von Krogh transformation, to measure total classical pathway complement activity in serum.

Testing Samples

Blood-Contacting Medical Devices

Any device or component that contacts circulating blood during routine use is a candidate for hemolysis testing. Typical samples submitted to accredited third-party laboratories include:

• Intravenous catheters, cannulae, infusion sets, syringes, and needles
• Extracorporeal circulation tubing, hemodialyzers, blood oxygenators, and ECMO circuit components
• Blood collection bags, filters, and transfusion sets
• Vascular stents, grafts, artificial heart valves, and blood pump components
• Guidewires, balloon catheters, and interventional accessories

Raw Materials, Coatings, and Extracts

Material developers submit polymer pellets, metal coupons, hydrophilic coatings, drug coatings, elastomers, adhesives, lubricants, and process fluids for hemolytic screening during design verification. Both the bulk material and its aqueous extract (leachables) can be evaluated.

Biological Samples for Complement Activity

For the CH50 variant of the assay, the sample is fresh human serum collected under controlled conditions, used promptly or stored frozen to preserve complement activity. This format is applied in clinical immunology laboratories.

Testing Items

Depending on the purpose of the study, the following measurements are typically reported:

• Hemolysis rate (%) by the direct contact method
• Hemolysis rate (%) by the indirect contact (extract) method
• Absorbance values of test, positive control, and negative control samples at 540 nm to 545 nm
• Hemolytic classification of the material (non-hemolytic, slightly hemolytic, hemolytic) per ASTM F756
• Visual and, where required, microscopic assessment of erythrocyte morphology and agglutination
• CH50 total complement activity in serum, expressed in U/mL, for clinical complement screening

Testing Methods

Direct Contact Method

The test article is placed in direct contact with diluted, freshly drawn anticoagulated blood (commonly rabbit or human blood anticoagulated with citrate or heparin). The mixture is incubated at 37 °C, typically for 2 to 4 hours with gentle periodic inversion. After incubation, the sample is centrifuged, and the absorbance of the supernatant is measured at 540 nm to 545 nm. This method is preferred for devices with large blood-contacting surfaces, such as oxygenator membranes and extracorporeal tubing.

Indirect Contact (Extraction) Method

The test article is extracted in a physiologic vehicle such as phosphate-buffered saline or 0.9% sodium chloride under defined conditions (for example, 37 °C for 24 hours, or accelerated conditions justified in the test plan). The resulting extract is then incubated with diluted blood at 37 °C, centrifuged, and read spectrophotometrically. This method is suitable for evaluating leachable substances and for materials that cannot be tested in direct contact.

Determination of the 50% Hemolysis Endpoint (CH50 Format)

In the complement assay, serial dilutions of patient or reference serum are incubated with a standardized suspension of antibody-sensitized sheep erythrocytes at 37 °C. Following centrifugation, the absorbance of each supernatant is measured, and the degree of lysis at each dilution is calculated. The serum dilution that produces exactly 50% lysis is identified from the lysis curve, historically by the von Krogh transformation, and the result is reported as CH50 units per milliliter. Typical adult reference intervals are commonly reported between approximately 26 and 55 U/mL, although each laboratory establishes its own range.

Calculation of Hemolysis Rate

For medical device testing, the hemolysis rate is calculated as: Hemolysis rate (%) = (Absorbance of test sample − Absorbance of negative control) / (Absorbance of positive control − Absorbance of negative control) × 100. Sterile distilled water or a detergent solution such as Triton X-100 typically serves as the positive control (100% lysis), while saline or buffer serves as the negative control (0% lysis).

Quality Controls and Acceptance Criteria

A run is considered valid only when the negative control shows negligible lysis and the positive control falls within the established laboratory range. For blood-contacting devices, a hemolysis rate of 5% or less is generally accepted as the pass criterion under ISO 10993-4 and GB/T 16886.4 evaluation practice. ASTM F756 further classifies materials as non-hemolytic (hemolysis index 0 to 2%), slightly hemolytic (2 to 5%), or hemolytic (greater than 5%).

Applications

• Biocompatibility evaluation of blood-contacting medical devices in support of regulatory submissions and design verification
• Comparative screening of candidate materials, surface treatments, and coatings during research and development
• Batch release and ongoing quality control for extracorporeal circulation and transfusion products
• Hemolytic risk assessment of pharmaceutical formulations, excipients, surfactants, nanoparticles, and disinfectant residues
• Clinical screening for complement deficiencies and monitoring of complement activation in immune-complex diseases
• Evaluation of blood storage containers and preservation solutions for erythrocyte integrity

FAQ

Q: Why is the 50% hemolysis point used as the endpoint?

A: The lysis-versus-dose curve is steepest at 50% hemolysis, so a given change in lytic activity produces the greatest change in measurable absorbance at this point. This maximizes assay sensitivity and reduces the influence of reading errors.

Q: Which standards govern the test?

A: ISO 10993-4 and GB/T 16886.4 define hemolysis testing as part of blood-interaction evaluation for medical devices, while ASTM F756 covers the analysis of hemolytic properties of materials. Clinical complement testing follows established immunology laboratory practice based on the CH50 principle.

Q: What blood is used for medical device testing?

A: Freshly drawn anticoagulated rabbit or human blood is most common. Blood is typically diluted with saline or buffer and used within a defined time window to ensure erythrocyte stability.

Q: When should the direct contact method be used instead of the extraction method?

A: The direct contact method best reflects actual use conditions for devices with significant blood-contacting surfaces. The extraction method is preferred when evaluating leachables, small or irregular specimens, or materials that physically interfere with spectrophotometric reading.

Q: What result indicates a device is acceptable?

A: A hemolysis rate of 5% or less is the widely accepted criterion, with classification bands in ASTM F756 providing additional granularity for material screening and comparison.

Q: Can this testing be outsourced?

A: Yes. Accredited third-party laboratories routinely perform hemolysis rate testing under ISO/IEC 17025 quality systems and in accordance with the relevant ISO, ASTM, and GB/T standards, providing traceable results suitable for regulatory submissions.